Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | IDH2 | P48735 | 3/20 | 0.46 |
| ▸ | CETP | P11597 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459990 | 0.94 | ALDH1A1 (0.48) | CNR1ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL3460910 | 0.88 | CNR1 (0.47) | CNR1ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL3462135 | 0.86 | ALDH1A1 (0.47) | CNR1ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL3461870 | 0.86 | CNR1 (0.44) | CNR1ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL3461493 | 0.85 | MAPT (0.44) | CNR1ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL3460857 | 0.85 | HCRTR2 (0.48) | CNR1ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL3461216 | 0.84 | MGLL (0.47) | CNR1ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL3461544 | 0.84 | ITGB1 (0.60) | CNR1ALDH1A1CA12CA1CA2 | |
| SCHEMBL13631953 | 0.82 | RORC (0.46) | ALDH1A1NPSR1RORC | |
| SCHEMBL3460076 | 0.80 | MCHR1 (0.48) | CNR1ALDH1A1NPSR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | CNR1 174/4885ALDH1A1 838/4885NPSR1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.